BioMarin Pharmaceutical Inc (BMRN)
BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy.
BMRN SEC Filing Email Alerts Service
Company Name: |
BioMarin Pharmaceutical Inc |
Website: |
www.bmrn.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding BMRN: |
61 |
Total Market Value Held by ETFs: |
$1.98B |
Total Market Capitalization: |
$16.55B |
% of Market Cap. Held by ETFs: |
11.98% |
|
|
March 28, 2024 10:00 PM Eastern
Buy (3.36 out of 4)
50th percentile
|
|